Pallas Capital Advisors LLC Purchases New Holdings in IQVIA Holdings Inc. $IQV

Pallas Capital Advisors LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 8,032 shares of the medical research company’s stock, valued at approximately $1,552,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Calamos Advisors LLC lifted its stake in shares of IQVIA by 268.1% in the 4th quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after acquiring an additional 137,441 shares during the period. Concurrent Investment Advisors LLC increased its stake in shares of IQVIA by 36.0% during the fourth quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company’s stock worth $2,693,000 after acquiring an additional 3,161 shares during the period. Munich Reinsurance Co Stock Corp in Munich purchased a new position in IQVIA during the fourth quarter worth about $3,444,000. Nippon Life Global Investors Americas Inc. lifted its position in IQVIA by 36.6% in the fourth quarter. Nippon Life Global Investors Americas Inc. now owns 79,400 shares of the medical research company’s stock valued at $17,898,000 after purchasing an additional 21,270 shares during the period. Finally, Los Angeles Capital Management LLC boosted its holdings in IQVIA by 3.5% in the 4th quarter. Los Angeles Capital Management LLC now owns 179,645 shares of the medical research company’s stock valued at $38,888,000 after purchasing an additional 6,118 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Trading Up 1.9%

Shares of IQV stock opened at $241.09 on Tuesday. The company has a market capitalization of $39.68 billion, a price-to-earnings ratio of 29.91, a PEG ratio of 2.01 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a 50-day moving average price of $207.80 and a 200 day moving average price of $186.72. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $251.36.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period last year, the company earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has approved a stock repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on IQV shares. BMO Capital Markets increased their target price on IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Robert W. Baird upped their price objective on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Royal Bank Of Canada increased their price objective on IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Barclays reissued an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Finally, Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

Insider Activity

In other IQVIA news, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider directly owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider directly owned 2,989 shares in the company, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 12,913 shares of company stock worth $3,098,793 in the last three months. 1.70% of the stock is owned by insiders.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.